Boston Scientific Corporation
bostonscientific.comWhat Do They Do?
Sells medical devices and therapies to hospitals, clinics and medical offices for diagnosing and treating cardiovascular, digestive and urological conditions.
10-K for FY2025, filed Feb 17, 2026Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of…View ↗
Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological…View ↗
We market our products and solutions to hospitals, clinics, outpatient facilities and medical offices in 127 countries worldwide. In…View ↗
How Do They Make Money?
Boston Scientific earns revenue mainly by selling single-use medical devices; buyers typically pay within 30 days in the U.S., with longer terms possible internationally. Consigned products are billed when used or implanted, while some heart-monitoring services are paid over their service periods.
10-K for FY2025, filed Feb 17, 2026We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our consolidated…View ↗
Transfer of control is evidenced upon passage of title and risk of loss to the customer unless we are required to provide additional…View ↗
We record a contract liability, or deferred revenue, when we have an obligation to provide a product or service to the customer and payment…View ↗
Contract liabilities are classified within Other current liabilities and Other long-term liabilities on our accompanying consolidated…View ↗
-
10-K for FY2025, filed Feb 17, 2026
FY2025 revenue by product or service ↗
$20.1B
-
10-K for FY2025, filed Feb 17, 2026
$20.1B ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Endoscopy
Sold outright
10-K for FY2025, filed Feb 17, 2026 |
15%
FY2022: 18%
|
Endoscopy, FY2025
$2.9B Sources
|
Sold outright |
|
Urology
Sold outright
10-K for FY2025, filed Feb 17, 2026 |
14%
FY2022: 14%
|
Urology, FY2025
$2.7B Sources
|
Sold outright |
|
Neuromodulation
Sold outright
|
6.0%
FY2022: 7.2%
|
Neuromodulation, FY2025
$1.2B Sources
|
Sold outright |
|
Interventional Cardiology & Vascular Therapies
Sold outright
10-K for FY2025, filed Feb 17, 2026 |
23% |
Interventional Cardiology & Vascular Therapies, FY2025
$4.6B Sources
|
Sold outright |
|
Watchman
Sold outright
10-K for FY2025, filed Feb 17, 2026 |
9.8%
FY2022: 8.0%
|
Watchman, FY2025
$2B Sources
|
Sold outright |
|
Electrophysiology
Sold outright
10-K for FY2025, filed Feb 17, 2026 |
17%
FY2022: 4.6%
|
Electrophysiology, FY2025
$3.3B Sources
|
Sold outright |
|
Cardiac Rhythm Management
Mix
10-K for FY2025, filed Feb 17, 2026 |
12%
FY2022: 17%
|
Cardiac Rhythm Management, FY2025
$2.3B Sources
|
Mix |
|
Interventional Oncology & Embolization
Sold outright
|
5.0% |
Interventional Oncology & Embolization, FY2025
$996M Sources
|
Sold outright |
Who Are Their Customers?
Hospitals, clinics, outpatient facilities and medical offices buy its products, with sales teams focused on physicians and hospital administrators. Most sales come from countries with direct sales organizations; distributors and dealers serve some other countries and markets.
10-K for FY2025, filed Feb 17, 2026
Do Revenues Turn Into Profits?
Yes. It kept 14 cents of every revenue dollar as net income in FY2025 and turned 18 cents into free cash flow.
10-K for FY2025, filed Feb 17, 2026
$3.6BView ↗
10-K for FY2025, filed Feb 17, 2026
$2.9BView ↗
10-K for FY2025, filed Feb 17, 2026
$3.7BView ↗
How Are They Changing?
-
May 18, 2026
Took a stake in MiRus with an option to acquire its TAVR business
The option is exercisable after clinical and regulatory milestones and would require additional payments.
Sources
8-K, filed May 18, 2026
Under the terms of the Investment Agreement, on May 15, 2026, the Company acquired, for a cash payment of $1.5 billion (exclusive of a $100…View ↗
Growing. Revenue grew 69% in 4 years, from $11.9B in FY2021 to $20.1B in FY2025, about 14% a year.
Electrophysiology's ablation mix
The older report listed pulsed-field ablation among several electrophysiology products; the latest says conversion from legacy treatments has made PFA the main component of the business and its revenue.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 17, 2026Rhythmia™ Mapping Systems, catheter-based, 3-D cardiac mapping and navigation solutions designed to help diagnose and guide treatment of a…View ↗
Since the launch of the FARAPULSE™ PFA System in 2024, we have observed rapid conversion from legacy treatment modalities to PFA. It is now…View ↗
Loading...
